Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum

[1]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[2]  A. Bartoš,et al.  Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis , 2008, European journal of neurology.

[3]  B. Kálmán,et al.  Autoantibodies and neurodegeneration in multiple sclerosis , 2008, Laboratory Investigation.

[4]  K. Blennow,et al.  Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype , 2007, European journal of neurology.

[5]  J. Kukal,et al.  Antibodies against light neurofilaments in multiple sclerosis patients , 2007, Acta neurologica Scandinavica.

[6]  B. '. ’t Hart,et al.  Immunization With Neurofilament Light Protein Induces Spastic Paresis and Axonal Degeneration in Biozzi ABH Mice , 2007, Journal of neuropathology and experimental neurology.

[7]  J. Kukal,et al.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis , 2007, Journal of Neurology.

[8]  Z. Meiner,et al.  Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects , 2006, Neuroscience Letters.

[9]  G. Giovannoni,et al.  The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders , 2006, Journal of Neuroimmunology.

[10]  Zhikai Cao,et al.  Low Avidity and Level of Serum Anti-Aβ Antibodies in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[11]  K. Kranda,et al.  Antibody formation against β-tubulin class III in response to brain trauma , 2006, Brain Research Bulletin.

[12]  J. Morvan,et al.  Use of Four Dengue Virus Antigens for Determination of Dengue Immune Status by Enzyme-Linked Immunosorbent Assay of Immunoglobulin G Avidity , 2005, Journal of Clinical Microbiology.

[13]  C. V. Jensen,et al.  Acute axonal damage predicts clinical outcome in patients with multiple sclerosis , 2005, Multiple sclerosis.

[14]  Ming-hui Zhao,et al.  Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. , 2005, Clinical immunology.

[15]  Xavier Deparis,et al.  Discrimination between Primary and Secondary Dengue Virus Infection by an Immunoglobulin G Avidity Test Using a Single Acute-Phase Serum Sample , 2005, Journal of Clinical Microbiology.

[16]  Héctor Martínez Alonso,et al.  Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2005, Acta neurologica Scandinavica.

[17]  J. Hafid,et al.  Reliability of Immunoglobulin G Antitoxoplasma Avidity Test and Effects of Treatment on Avidity Indexes of Infants and Pregnant Women , 2004, Clinical Diagnostic Laboratory Immunology.

[18]  A. Saiz,et al.  Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis , 2004, Neuroscience Letters.

[19]  M. Zaffaroni.  Biological indicators of the neurodegenerative phase of multiple sclerosis , 2003, Neurological Sciences.

[20]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[21]  S. Cook,et al.  Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.

[22]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[23]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[24]  H. Reiber,et al.  Tau protein in cerebrospinal fluid (CSF): a blood–CSF barrier related evaluation in patients with various neurological diseases , 2001, Neuroscience Letters.

[25]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[26]  H. Kikuta,et al.  Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection , 1996, Clinical and diagnostic laboratory immunology.

[27]  T. Ternynck,et al.  The natural autoantibodies system: between hypotheses and facts. , 1993, Molecular immunology.

[28]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[29]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[30]  A. Bartoš,et al.  Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. , 2009, Folia biologica.

[31]  K. Kranda,et al.  Antibody formation against beta-tubulin class III in response to brain trauma. , 2006, Brain research bulletin.

[32]  C. Pannuti,et al.  Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. , 1997, Journal of medical virology.